The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | POSEIDON: 4 year follow up of durvalumab and tremelimumab in NSCLC
Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses data from the 4 year follow up of the Phase III POSEIDON trial (NCT03164616) of durvalumab and tremelimumab in patients with metastatic non small-cell lung cancer (NSCLC). Patients were randomized to receive durvalumab and tremelimumab with chemotherapy, durvalumab monotherapy with chemotherapy or chemotherapy alone. In the follow up, long term survival was reported in the triple treatment arm, where patients with non-squamous, low PD-L1 NSCLC fared the best. Patients with hard to treat mutations such as STK11, KRAS and KEAP1 additionally reported favorable outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
